Sun Pharma Q4 Review - Domestic Formulation On Steady Footing: Motilal Oswal
Sun Pharma headquarters in Mumbai. (Photographer: Kanishka Sonthalia/Bloomberg)

Sun Pharma Q4 Review - Domestic Formulation On Steady Footing: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Sun Pharmaceutical Industries Ltd. delivered a Q4 FY21 performance marginally below our expectations, weighed by moderation in U.S. and active pharmaceutical ingredient sales.

Domestic formulation business growth has been strengthening for three consecutive quarters now.

Marketing efforts are driving strong performance in Ilumya, a specialty product – 51% YoY growth was reported for FY21.

It further intends to build a biosimilar portfolio for launch over CY28–30.

We raise our earnings estimate by 9%/8% for FY22E/FY23E, factoring in:

  • continued ramp-up in llumya, led by the specialty portfolio,

  • healthy growth in the base DF portfolio as well as additions to the Covid-19 portfolio, and

  • subsequently better operating leverage.

Click on the attachment to read the full report:

Motilal Oswal Sun Pharma Q4FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.